The U.S. Food and Drug Administration announced a Roadmap to Reducing Animal Testing in Preclinical Safety Studies by leveraging more effective, human relevant methods including technologies like our Human-on-a-Chip!
This exciting announcement outlines a 3-year strategic roadmap for implementing the use of New Approach Methodologies (NAMs) and represents a significant step forward in gaining widespread regulatory adoption. This is the product of a long-standing, collective effort from government, advocacy groups, and industry marking a significant shift into a new chapter for drug discovery.
"This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments for Americans while reducing animal use...We can get safer treatments to patients faster and more reliably, while also reducing R&D costs and drug prices. It is a win-win for public health and ethics." -Martin A. Makary, M.D., M.P.H, FDA Commissioner
The FDA plans to accelerate the validation and adoption of NAMs by working with other federal agencies through the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM).